Search EN menu en EIB GROUP CLIENT PORTAL
Close EIB GROUP CLIENT PORTAL
Search
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages

ALTERMED

Signature(s)

Amount
€ 11,000,000
Sector(s)
Services : € 11,000,000
Signature date(s)
3/07/2008 : € 3,000,000
13/12/2007 : € 8,000,000
Link to source
Data sheet
ALTERMED
Other links
Summary sheet
Altermed
Related press
Launch of AlterMed

Summary sheet

Release date
14 November 2007
Status
Reference
Signed | 13/12/2007
20070209
Project name
Promoter - financial intermediary
Altermed
Viveris Management
Proposed EIB finance (Approximate amount)
Total cost (Approximate amount)
Up to EUR 11 million or 25% of the total commitments in any of the targeted compartments, whichever is lower.
The target size of AlterMed Maghreb is expected to be EUR 25 million, and EUR 30 million for AlterMed APEF.
Location
Sector(s)
Description
Objectives

The proposed operation consists in an equity participation under EC MEDA II risk capital resources in two compartments of AlterMed: AlterMed Maghreb investing primarily in Morocco; and AlterMed Alternative Private Equity Fund (APEF) investing primarily in Tunisia.

The two compartments in which the Bank intends to invest display innovative features. AlterMed Maghreb will target primarily leveraged buy-outs (LBOs), thereby supporting a niche not fully covered by other funds in Morocco. AlterMed APEF will support companies to be listed in the Tunisian alternative market, an initiative expected to be implemented by the end of 2007 and strongly supported by the Tunisian government as an opportunity to substantially increase the capitalisation of the stock market, still in its infancy stage.

Environmental aspects
Procurement

Not applicable

Not applicable

Link to source
Summary sheet
Altermed
Other links
Data sheet
ALTERMED
Related press
Launch of AlterMed

Disclaimer

Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

News & Stories

Link to source
Related press
Launch of AlterMed
Other links
Data sheet
ALTERMED
Summary sheet
Altermed

General enquiries and comments

The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, the EIB can be contacted through its external offices.
Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

Media enquiries

Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

Complaints mechanism

Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

Zero tolerance against fraud and corruption

The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Investigations Division. All reports will be treated as strictly confidential and handled in line with EIB investigation procedures and the EIB Group Anti-Fraud Policy.

Related publications